title: Marked decrease in plasma apolipoprotein A-I and high density lipoprotein-cholesterol in a case with Werner syndrome.
abstract: The patient was a 39-year-old Japanese male with a body height of 160 cm and weight of 48 kg who was diagnosed as Werner syndrome of homozygote for mutation 4. His plasma total cholesterol (TC), triglycerides (TGs), high density lipoprotein-cholesterol (HDL-C) and apolipoprotein A-I (apo A-I) levels were 7.2, 2.1, 1 mmol/l and 128 mg/dl, respectively. During the clinical course of treatment of this patient, his plasma levels of HDL-C and apo A-I declined drastically to levels of as low as 0.2 mmol/l and 10 mg/dl, respectively, with concurrent reciprocal increase in plasma TG levels. Plasma HDL-C, apo A-I and TG levels gradually returned to original values. Lipoprotein lipase activity and mass in post-heparin plasma were markedly low when the apo A-I and HDL-C levels decreased to 10 mg/dl and 0.21 mmol/l, respectively, and these values improved when the apo A-I and HDL-C levels returned to more normal values of 106 mg/dl and 0.94 mmol/l, respectively. The result of direct sequence of the exon 3 and 4, and the promoter region of the apo A-I gene of the patient revealed no single nucleotide changes. These results suggest that in the present patient, impaired hydrolysis of TGs in TG-rich lipoproteins, is due at least in part to a decreased LPL enzyme level, reduced the formation of nascent HDL, resulting in unusually low plasma levels of HDL-C and apo A-I.
authors.affiliation: Health Sciences Center Chiba University, Chiba, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Kobayashi
authors.forename: S
authors.initials: S
authors.lastname: Murano
authors.forename: K
authors.initials: K
authors.lastname: Yokote
authors.forename: S
authors.initials: S
authors.lastname: Mori
authors.forename: A
authors.initials: A
authors.lastname: Matsunaga
authors.forename: J
authors.initials: J
authors.lastname: Sasaki
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: H
authors.initials: H
authors.lastname: Bujo
authors.forename: Y
authors.initials: Y
authors.lastname: Saito
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D016632:Apolipoprotein A-I / Q000097:blood* / Q000235:genetics; D001629:Bezafibrate / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D017035:Pravastatin / Q000627:therapeutic use; D011341:Probucol / Q000627:therapeutic use; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014898:Werner Syndrome / Q000097:blood* / Q000188:drug therapy / Q000235:genetics
chemical_list: D000924:Anticholesteremic Agents; D016632:Apolipoprotein A-I; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D014280:Triglycerides; D017035:Pravastatin; D011341:Probucol; D001629:Bezafibrate